Notice: The called constructor method for WP_Widget is deprecated since version 4.3.0! Use
instead. in /hermes/bosnaweb01a/b2262/ipw.patentba/public_html/wp/wp-includes/functions.php on line 3457

Notice: The called constructor method for WP_Widget is deprecated since version 4.3.0! Use
instead. in /hermes/bosnaweb01a/b2262/ipw.patentba/public_html/wp/wp-includes/functions.php on line 3457

Notice: The called constructor method for WP_Widget is deprecated since version 4.3.0! Use
instead. in /hermes/bosnaweb01a/b2262/ipw.patentba/public_html/wp/wp-includes/functions.php on line 3457
Patent Baristas

As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan.  During the 2012 BIO International Convention, a full-day of program has been devoted to China and will target both Chinese and Western delegations.

As part of China Day, BIO explores questions about the changing landscape for innovation, healthcare reform, global regulatory trends and one of the most pressing questions for many attendees:  What is the right way to partner in China?  Speakers with decades of experience conducting business in the Chinese life sciences sector, such as George Baeder, Partner at Monitor Group Asia, and Li Chen, President and CEO of Hua Medicine, help guide discussions.

In another session, the World Health Organization (WHO) talked about the Pandemic Influenza Preparedness (PIP) Framework, which established requirements related to the sharing of influenza viruses and access to vaccines and other benefits.  The WHO is now working to implement the PIP Framework internationally.  A panel today, comprised of experts from the WHO and its Member States, the U.S. government, and large and small vaccine manufacturers and developers, discussed implementation progress to date and the broad implications of the Framework for vaccine manufacturers globally.

Recognizing the role of industry as an important contributor to technology innovation and transfer in addressing the challenges of pandemic influenza preparedness and response,

1. ADOPTS, in accordance with Article 23 of the WHO Constitution, the Pandemic Influenza Preparedness Framework, including its annexes;

2. URGES Member States: (1) to implement the Pandemic Influenza Preparedness Framework; (2) to support actively the wide implementation of the Pandemic Influenza Preparedness Framework, and (3) to consider providing adequate resources for its implementation;

3. CALLS UPON relevant stakeholders to give priority to implementing the Pandemic Influenza Preparedness Framework;

4. REQUESTS the Director-General, in consultation with the Advisory Group: (1) to implement the Pandemic Influenza Preparedness Framework; (2) to monitor and review the operation of the Pandemic Influenza Preparedness Framework and all of its components, in accordance with its provisions; (3) to report, on a biennial basis, to the World Health Assembly through the Executive Board on progress in the implementation of this resolution. Tenth plenary meeting, 24 May 2011 A64/VR/10

Meanwhile, smaller biotech’s seem to be stepping up to fill the gap of moving products into treatments and diagnostics for neglected diseases such as tuberculosis, malaria and dengue fever, which because they typically affect impoverished third-world countries have been considered noncommercial markets.

According to David Steinmiller, COO of OPKO Diagnostics LLC of Woburn, part of the challenge is that there is little to no money to be made in neglected diseases, and there is a high cost to get regulatory approvals and to protect intellectual property in multiple countries.

Steinmiller made his comments at a panel centered on a new report by BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) on participation of small- to medium-sized biotech companies in neglected diseases.

The report found that 134 biotech companies—5 percent of the total number of biotechs—are participating in neglected disease research and development. That translates into 39 percent of the 191 new drugs, vaccines, and diagnostics in development for neglected diseases. Neglected diseases affect more than 1 billion people, according to BVGH CEO Donald Joseph.

By comparison, big pharma participate in 75 of projects, though Joseph pointed out that there are fewer than 20 big pharma companies and their projects are on a larger scale, spending more and running complex clinical trials in multiple countries.

The BIO 2012 convention in Boston, which runs June 18-21 at the Boston Convention and Exhibition Center, expects to attract about 15,500 attendees—one third of them international.

  Print This Post Print This Post  

For the fourth year in a row, BIO is working with bloggers and reporters from around the country (and Canada) to provide attendees with an inside look of what’s happening at the 2012 BIO International Convention in Boston.

Be sure to check out their coverage on BIOtechNOW throughout the event and at their blogs:

Biotech Blog: Yali Friedman & Rolf Taylor

Yali Friedman, Ph.D., is founder of thinkBiotech and chief editor of the Journal of Commercial Biotechnology. His book, Building Biotechnology, is used as a course text in dozens of biotechnology programs. His other books include Best Practices in Biotechnology Education and Best Practices in Biotechnology Business Development. He is also a member of the board of directors and steering group of the Center for Policy on Emerging Technologies, serves on the science advisory board of Chakra Biotech, and also serves as a judge for the Biotech Humanitarian Award and the Maryland Incubator Company of the Year Award.

Rolf Taylor is a development consultant at EASE Fundraising System, a development associate at the American Liver Foundation, and a special projects & vlogger at the Journal of Commercial Biotechnology. He plans and executes communications and development programs to support medical products, devices and diagnostics, association and foundation

The Cross-Border Biotech Blog, Christian Hartmann

Christian Hartmann has worked for the past 3.5 years at Deloitte Canada as an Account Manager supporting the National Life Sciences and Mining Practices. He has worked on large pharmaceutical accounts and works to develop relationships with early stage biotechnology companies. He also represents Deloitte at key industry events including BioFinance and BIO. Christian received his diploma in Biotechnology from Seneca College and has worked in industry as part of the team that developed an early detection kit for Myocardial Infarction at Spectral Diagnostics. He has also owned and operated a business in the Health Food industry gaining approvals from Health Canada, FDA, CRA and CITIES  to import and distribute a novel plant based supplement product for sale in Canada and the U.S.

Fierce Biotech, John Carroll

John D. Carroll is a biotech analyst with 32 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. John is based in Vermont and Texas.

Genome Alberta, Mike Spear

Mike Spear is Director of Corporate communications at Genome Alberta. After an extensive career in the media as a Producer, Executive Producer, and Program Manager, Mike moved over to other side of the journalists microphone when he joined the non-profit Alberta Beef Producers as Communications and Marketing Manager. After guiding and developing a new marketing plan to lead them through to 2009, it was time to look for a new challenge and he landed here with Genome Alberta in July of 2007. As Director of Corporate Communications Mike is an important part of Genome Alberta’s goal of “taking the Alberta Advantage to the world of international science”.

Life Science Leader, Rob Wright

As the chief editor of Life Science Leader magazine, Rob develops editorial content in the pharmaceutical and biotechnology industries. The focus of their audience is management level decision makers, such as the c-suite and director level, providing information regarding pre-clinical drug discovery and development up to commercialization. Life Science Leader is a B2B publication having 25,000 subscribers in the U.S. and over 50,000 globally via their digital version. Rob has 17 years of pharmaceutical industry experience in variety of roles, including sales, training, and management with OTC and prescription products, medical device, surgical implants and diagnostic tests. Previous publications primarily focused on the post commercialization aspect of the industry. Additional experience includes serving as a speaker at a variety of international marketing and pharmaceutical conferences.

Lillypad, Yasmein Asi & Robyn Orth

Yasmein Asi is a digital government affairs consultant at Eli Lilly and Company. Before being hired full-time in June 2011, she was a government affairs intern at Eli Lilly. She received her BA in Politic Science and Communication in 2008 before receiving her Masters in International Policy & Development.

Robyn Orth is a consultant covering digital government affairs at Eli Lilly and Company. Before being hired full-time, she was an international affairs intern. She received a BA in Latin American Studies and History at Tulane University before earning an MA in Latin American Studies at Georgetown University. Robyn specializes in Latin American studies, networking, administration and research.

MIT Technology Review, Susan Young

Susan Young is the biomedicine editor for Technology Review and looks for stories where technology stands to improve human health or advance our understanding of the human condition. She joined Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature.

Patent Baristas, Stephen Jenei

Editor-in-Chief Barista Stephen Jenei is the founder and owner of Patent Baristas. He is also a patent attorney and Owner of the innovative law firm Jenei LLC.  When not serving up patent chat over a cup of java, he’s handling a diverse intellectual property practice in the biotechnology, pharmaceutical and chemical fields for leading universities, research hospitals and research institutes, as well as biotechnology and pharmaceutical companies ranging from start-up to Fortune 500 companies. He works closely with biotechnology and emerging growth companies to brew up successful new business models, execute strategic intellectual property  protection and litigation, and structure and negotiate technology transactions.

Patent Docs, Kevin Noonan & Don Zuhn

Kevin Noonan has extensive experience in biotechnology and the chemical arts. Dr. Noonan brings more than 10 years of experience as a molecular biologist working on high-technology problems to his legal work. He has wide experience in all aspects of patent prosecution, interference, litigation, and client counseling on validity, infringement, and patenting strategy matters. He represents pharmaceutical and biotechnology companies both large and small, and he is particularly experienced in representing university clients in both patent prosecution and licensing to outside investors.

Don Zuhn has more than a decade of experience in all aspects of patent prosecution, litigation, counseling, and licensing. He represents a variety of clients, including biotechnology and pharmaceutical companies both large and small, and universities.  Don joined MBHB in 1998. He maintained a full-time position as a law clerk while attending law school at night until his graduation in 2002.

Snapshot, Betsy Raymond Stevenson

RaymondStevenson Healthcare Communications’ client roster includes leading pharmaceutical and biotechnology companies. Prior to founding RaymondStevenson in 2007, Betsy worked with Pfizer Inc’s Corporate Communications group, where she developed strategy and directed international and top-tier media relations for the company’s Oncology and Central Nervous System portfolios and served as media counsel for Pfizer’s Chief Medical Officer and Senior Vice President Worldwide Development. Betsy led the team that developed Pfizer’s U.S. Research and Development communications and re-branding strategies for the company’s Warner-Lambert merger and Pharmacia acquisition.

Trade Secrets, Brady Huggett

Brady Huggett is Managing Editor for BioWorld Today, BioWorld Financial Watch, BioWorld Week and BioWorld International, and serves as overseer for the organization’s sourcebooks and BioWorld Phase III Report.

Xconomy, Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, his passionate coverage of biotechnology won many awards for The Seattle Times.

While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, the Society of American Business Editors and Writers award, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service. At Xconomy, he was honored in 2012 as a finalist for the Gerald Loeb Award, and received a SABEW award for biotech columns.

Now, let’s get to down to business.

  Print This Post Print This Post  

Former Secretary of Health and Human Services to Lead Panel at 2012 BIO International Convention Panel Calls for the Urgent Need to Better Fuel the Biotechnology Pipeline with a Diverse Workforce

WHAT:                Thought leaders of industry, education, and government will gather to discuss fostering and recruiting a more diverse workforce in the biotechnology industry at the Diversity Summit, a special program on Monday, June 18 at 3:00 p.m. The event will be featured at the 2012 BIO International Convention, the global event for biotechnology, taking place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA.

The 2012 Diversity Summit – Fueling our Industry Pipeline: An Eye on Education will consist of a panel of experts discussing the importance of recruiting and fostering a diverse workforce in the biotechnology field.

WHO:                  Moderator: Dr. Louis W. Sullivan, Former Secretary of Health and Human Services, President Emeritus, Morehouse School of Medicine

·       Dr. Brandi Kaye Freeman, Pediatric Fellow, Trustee to the Board of Trustees of the National Medical Association, Chairperson of the Post-Graduate Physician Scientific Section
·       Dr. Norbert G. Riedel, Corporate Vice President, Chief Science and Innovation Officer of Baxter International Inc.
·       Dr. Eugene M. DeLoatch, Dean and Full Professor of the Clarence M. Mitchell Jr. School of Engineering, Morgan State University

WHEN:                Monday June 20th
3:00 pm

WHERE:              Room 211

  Print This Post Print This Post  

The Biotechnology Industry Organization (BIO) will take the wraps off some findings from a report on the role of Intellectual Property Rights (IPRs) in encouraging upstream R&D and downstream commercialization in biotechnology at the 2012 BIO International Convention in Boston.

“Taking Stock: the Gains of Global Biotechnology Research from IPRs”

The report, titled “Taking Stock: the Gains of Global Biotechnology Research from IPRs,” will bring together experts to discuss how IPRs have affected innovation and the development of new biotechnologies and whether they contribute to growth in partnerships and other models of collaboration between biotechnology R&D actors such as universities, small and medium sized entities (SMEs) and pharmaceutical manufacturers.

The session will unveil a new report, titled “Taking Stock: the Gains of Global Biotechnology Research from IPRs,” which focuses on the extent to which intellectual property rights play a role in encouraging upstream R&D and downstream commercialization in biotechnology in developed and developing countries.

BIO International Convention, Boston Convention & Exhibition Center, Room 259A

Tuesday, June 19, 2:00 pm – 3:30 pm

This report will highlight the need for intellectual property rights and the importance for developing countries to advance in the biotechnology field. In order for countries to build a strong and thriving biotech sector, strong intellectual property protection is a must.

  Print This Post Print This Post  

With four days left until BIO 2012 in Boston, EvaluatePharma’s World Preview 2018 warns of excessive R&D spending, but patent cliff may “liberate” drug companies.  EvaluatePharma released a report on the pharmaceutical industry entitled “World Preview 2018: Embracing the Patent Cliff,” whcih includes analysts’ forecasts on which companies and products will come out as winners in the years ahead.

This report is critical for everyone in the pharma arena.  Lots of great info! The forecasts are based on EvaluatePharma’s coverage of the world’s largest 3,500 pharmaceutical and biotech companies.

The market for prescription drugs, based on the consensus forecast for the leading 500 pharmaceutical and biotechnology companies, will grow by 3.1 percent per year between 2011 and 2018 to reach $885 billion, according to World Preview 2018.

EvaluatePharma’s analysis shows that more than $290 billion of prescription drug sales are at risk from patent expirations during that time frame. As companies have worked to rebuild their pipeline, the pharmaceutical industry has spent $1.1 trillion over the last 10 years on research and development, according to the report.

“It is often said there is an R&D productivity issue, but is it just poor portfolio strategy and investment choices? Is too much money being spent chasing too few quality R&D projects?” asks Anthony Raeside, Head of Research. “The patent cliff in its own right may not be the problem, but rather the way management reacts to it.”

The World Preview 2018 report will be officially released at the 2012 BIO International Convention, held June 18-21 in Boston. A hard-copy Executive Summary of World Preview 2018 will be available at EvaluatePharma’s Booth 1421.

In addition to assessing forecast trends in prescription drug sales and R&D spending, World Preview 2018 also looks at therapy area growth and the performance of marketed and pipeline products. Among this year’s key findings:

Novartis will emerge as a clear leader in 2018, with sales forecast to reach $51.3 billion by that year. That’s $3 billion ahead of its closest competitors, Pfizer and Sanofi.

Gilead Sciences is set to climb the most positions within the top 20, moving up seven places to number 15 with prescription sales of $15.1 billion in 2018, thanks in large part to the company’s strong HIV franchise and impressive forecasts for GS-7977, its recently acquired development stage hepatitis C product.

Looking at which products will top the sales charts, Merck & Co.’s Type 2 diabetes therapy franchise, Januvia/Janumet, will reign with sales forecast showing a 10 percent compound annual growth rate between 2011 and 2018 to reach $9.7 billion in sales.

Gilead’s potential new hepatitis C polymerase inhibitor, GS-7977 — forecast to achieve $5.4 billion in sales in 2018 — is the highest ranked R&D product in 2018.

In this year’s report, EvaluatePharma has added, for the first time, a geographic analysis looking at the performance of the U.S., Europe and Japan pharmaceutical markets in 2011. The analysis reveals major market growth flat-lining in 2011, with little or no growth in the U.S., a decline in Europe, and modest growth in Japan.

Complimentary copies of World Preview 2018 are available for download here.

  Print This Post Print This Post  

The 2012 BIO International Convention will feature an educational track devoted to Biotech Patenting and Tech Transfer to discuss legal and legislative developments and how they are likely to impact biotech companies.   Hosted by the Biotechnology Industry Organization(BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA.

I’ll be in attendance as well as participating in BIO’s blogger network throughout the week. If you’d like to meet up during the conference, drop me a note and we’ll schedule some time to have coffee together. email the Baristas

You can follow Patent Baristas here or @PatentBaristas.  You can get BIO updates from BIOtechNOW, an online portal and newsletter produced by BIO or @BIOConvention.

Session highlights include:

Recent Developments in Patentability: Prometheus, Myriad, Classen and the Patentability of Diagnostic Methods

No, unfortunately this is not about the Charlize Theron movie.  Here, a panel of distinguished patent-law experts and practitioners will discuss the leading cases on patent eligibility of diagnostic methods, focusing on the Prometheus case in the Supreme Court of the United States and the Myriad Genetics and Classen cases in the Federal Circuit. The panel will discuss the implications of these cases for biotech patents and the future of biotech innovation, including personalized medicine.

Tuesday, June 19, 8:30 a.m. – 9:45 a.m.

Moderator: Mark Fleming, Partner, Wilmer Cutler Pickering Hale and Dorr LLP

Speakers: Seth Waxman, Partner, Wilmer Cutler Pickering Hale and Dorr LLP, Kevin Marks, Vice President, Roche Molecular Diagnostics and John Whealan, Associate Dean for Intellectual Property Law, George Washington University Law School

Prior User Rights and Trade Secrets: A New IP Option Replacing Patents to Secure Freedom – to – Operate for Internally Used Innovations in Biotechnology

Trade secret asset management is a strategic imperative as companies develop and market their innovations. The session will help companies answer the question – Is it worth the trouble to patent internally – used technology? Additionally, the panel will discuss whether Prior User Rights, a defense against infringement of a later patent, is a better option for companies.

Tuesday, June 19, 2:00 p.m. – 3:30 p.m.

Moderators: R. Mark Halligan, Partner, Nixon Peabody LLP and Thomas Kelley, Consulting Patent Counsel, Monsanto Company

Speaker: Jason Duncan, Associate General Counsel, EMD, Serono, Inc.

IP Issues Affecting Biomarker Diagnostics and Personalized Medicine

A panel of international will discuss:how and why recent legislation and court decisions defining “patent-eligible” products and methods will impact the patent protection that is available for biomarker diagnostic products and services; scientific issues that impact patent procurement and the scope of patent protection and when the applicant must present the data and cross-border and multi-party (joint) infringement considerations that impact companies’ ability to enforce patents against competitor/copiers.

Wednesday, June 20, 2:00 p.m. – 3:30 p.m.

Moderator: Jan Skouv, Director IPR, Exiqon A/S

Speakers: David Gaas, Partner, Marshall, Gerstein & Borun, LLP;  Thorlakur Jonsson, Director of Intellectual Property, deCODE genetics e; Simon O’Brien, Chartered Patent Attorney, D. Young & Co. and John Tessensohn, Board Member, Shusaku Yamamoto Patent Attorneys

American Invents Act Comes to Campus: the Impact on Commercialization and Technology Transfer Offices

The recently enacted Leahy-Smith America Invents Act 2011 (“Act”) is the most significant change to U.S. patent law in recent decades. Certain provisions of the Act will greatly affect how universities and non-profit research institutions disclose technological information, implement IP strategies, and license their innovations to third parties. This panel will discuss the impact of the Act on the missions and policies of universities and non-profit institutions as well as address new strategies for universities and non-profits.

Thursday, June 21, 8:30 a.m. – 9:45 a.m.

Speakers: Fernando Alberdi, Partner, Honigman Miller Schwartz and Cohn; Charles Niebylki, Senior Intellectual Property Advisor, National Institute of Health (NIH;, Robin Rasor, Director of Licensing, University of Michigan and Christina Sarris, Senior Technology Transfer Policy Advisor, National Institute of Health (NIH)

  Print This Post Print This Post  

It’s day numbah five until BIO 2012 Convention hits beantown in a flurry of activity, Chris Christie, the Republican governor of New Jersey known for his combative style, was named the BIO 2012 Governor of the Year.

The Award was presented to Governor Christie at a special ceremony at the State House in Trenton joined by BIO Board Member and Celgene Executive Vice President and Chief Operations Officer Perry A. Karsen and BIO Vice President for Alliance Development and State Government Relations Fritz Bittenbender.

In nominating the Governor, BioNJ cited his leadership in promoting a better business environment for all businesses in New Jersey, his support of the Technology Business Tax Certificate Transfer Program, the doubling of the R&D Tax Credit and the naming of BioNJ to administer the Life Science Talent Network.  His support of the biotechnology industry, along with that of Lt. Kim Guadagno builds on a long tradition of State Government support that has helped to make New Jersey one of the leading bioclusters in the world.

The BIO conference will hit Boston’s convention center on Monday, with 4,000 companies and 15,000 attendees.  While many of the biggest drug names in New Jersey, like Merck and Co., really are pharmaceutical companies, not biotechs, the BIO organization decided in favor of Christie. It could be that New Jersey has seen a massive of jobs over the past few years as big pharma’s blockbuster drugs go off patent.  This starts to make biotech even more appealing.

Christie will be in chowdah-town next week spending time in the state’s pavilion, which is designed to lure new companies to the state.

At least Chistie has shown that he can be the bigger man.

  Print This Post Print This Post  

“The world is shifting to an innovation economy and nobody does innovation better than America. ”
—President Obama, December 6, 2011

On September 16, 2011, President Obama announced that his Administration would release a National Bioeconomy Blueprint as part of his commitment to supporting scientific discovery and technological breakthroughs to ensure sustainable economic growth, improve the health of the population, and move toward a clean energy future. The 2012 National Bioeconomy Blueprint has two purposes: to lay out strategic objectives that will help realize the full potential of the U. S.  bioeconomy and to highlight early achievements toward those objectives.

Technological innovation is a significant driver of economic growth, and the U.S. bioeconomy represents a growing sector of this technology-fueled economy.   According to the USDA, U. S. revenues in 2010 from genetically modified crops were approximately $76 billion.  Beyond agriculture, based on the best available estimate, 2010 U. S. revenues from industrial biotechnology—fuels, materials, chemicals, and industrial enzymes derived from genetically modified systems—were approximately $100 billion.

The growth of today’s U. S. bioeconomy is due in large part to the development of three foundational technologies: genetic engineering, DNA sequencing, and automated high-throughput manipulations of biomolecules.

The National Bioeconomy Blueprint describes five strategic objectives for a bioeconomy with the potential to generate economic growth and address societal needs.

1.  Support R&D investments that will provide the foundation for the future U. S.  bioeconomy.

TCoordinated strategic programs and targeted investments will accelerate progress in biological research and technology areas, and this in turn will drive discovery for an American bioeconomy.

Expand and Develop Essential Bioeconomy Technologies – Multiagency collaborations for emerging foundational technologies such as synthetic biology, biology-related information technologies, proteomics, and others are being fostered in order to grow the bioeconomy.

Integrate Approaches across Fields – The Administration will prioritize additional multidisciplinary efforts to enable biological research at the boundaries of fields, such as physics, chemistry, engineering, computer sciences, and mathematics, that support the bioeconomy.

Implement Improved Funding Mechanisms – Creating or modifying funding mechanisms to support creative, high-risk/high-reward research can enable researchers to pursue daring—and potentially groundbreaking—research that may be constrained by typical funding mechanisms or approaches.

2.  Facilitate the transition of bioinventions from research lab to market, including an increased focus on translational and regulatory sciences.

Accelerate Progress to Market – To capitalize on the promise of the newly reauthorized Small Business Innovation Research (SBIR) program, agencies should evaluate and update SBIR programs. Some relevant objectives include reducing application response times, hiring/training program staff to enhance relevant in-house experience, and increasing the use of industry experts as peer reviewers to evaluate industry proposals.

Enhance Entrepreneurship at Universities –  Integrating entrepreneurship and industry involvement into the university research experience will facilitate the path from research to commercialization and help innovative ideas reach the marketplace. Innovative programs that enhance entrepreneurial activities at universities are needed to help academic discoveries become commercial realities.

Utilize Federal Procurement Authority – To drive the creation and growth of new bioeconomy markets, Federal agencies should prioritize procurement of biobased and sustainable products where appropriate and cost-effective.

3.  Develop and reform regulations to reduce barriers, increase the speed and predictability of regulatory processes, and reduce costs while protecting human and environmental health.

Moving forward: Improved regulatory processes will help rapidly and safely achieve the promise of the future bioeconomy.

Improve Regulatory Processes and Regulations – To reduce costs and impediments to investments but without compromising safety and efficiency, attention should be given to application review times, sequential reviews by multiple agencies should be coordinated to allow parallel reviews, and specific guidance should be issued in response to stakeholder needs.

Collaborate with Stakeholders – Federal agencies should focus on building new, and augmenting existing, stakeholder collaborations to inform efforts, streamline processes, and reduce costs and response times, while preserving safety and ensuring substantive benefit to public

4.  Update training programs and align academic institution incentives with student training for national workforce needs.

Employer-Educator Partnerships – Foster increased industry participation in the development of programs and in training students at all levels for the future bioeconomy workforce.

Reengineer Training Programs – Incentives for academic institutions to enhance entrepreneurship and restructure training programs would better prepare the future bioeconomy workforce, whether individuals are bound for careers in industry or academia.

5.  Identify and support opportunities for the development of public-private partnerships and precompetitive collaborations—where competitors pool resources, knowledge, and expertise to learn from successes and failures.

Catalyze Public-Private Partnerships – Federal agencies are encouraged to broadly pursue opportunities for effective public-private partnerships in health, energy, agriculture, and manufacturing to leverage Federal investments and industry investments and expertise.

See the complete National Bioeconomy Blueprint 2012 here.

  Print This Post Print This Post